Bolt Biotherapeutics (BOLT) Competitors

Bolt Biotherapeutics logo
$5.06 -0.04 (-0.78%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$5.09 +0.03 (+0.59%)
As of 11/19/2026 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BOLT vs. PLRX, ATNM, HOWL, GANX, and CNTB

Should you buy Bolt Biotherapeutics stock or one of its competitors? Bolt Biotherapeutics's main competitors and comparable companies include Pliant Therapeutics (PLRX), Actinium Pharmaceuticals (ATNM), Werewolf Therapeutics (HOWL), Gain Therapeutics (GANX), and Connect Biopharma (CNTB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Bolt Biotherapeutics compare to Pliant Therapeutics?

Pliant Therapeutics (NASDAQ:PLRX) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Bolt Biotherapeutics has higher revenue and earnings than Pliant Therapeutics. Pliant Therapeutics is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pliant Therapeutics$1.58M24.33-$149.34M-$1.45N/A
Bolt Biotherapeutics$7.70M1.72-$33.38M-$14.97N/A

97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 8.7% of Pliant Therapeutics shares are owned by insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Pliant Therapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 383.87%. Bolt Biotherapeutics has a consensus target price of $14.50, suggesting a potential upside of 186.56%. Given Pliant Therapeutics' higher probable upside, research analysts clearly believe Pliant Therapeutics is more favorable than Bolt Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pliant Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Bolt Biotherapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

In the previous week, Bolt Biotherapeutics had 4 more articles in the media than Pliant Therapeutics. MarketBeat recorded 6 mentions for Bolt Biotherapeutics and 2 mentions for Pliant Therapeutics. Bolt Biotherapeutics' average media sentiment score of 1.03 beat Pliant Therapeutics' score of -0.75 indicating that Bolt Biotherapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pliant Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative
Bolt Biotherapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Pliant Therapeutics has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Pliant Therapeutics' return on equity of -57.13% beat Bolt Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Pliant TherapeuticsN/A -57.13% -44.97%
Bolt Biotherapeutics -611.47%-154.11%-57.59%

Pliant Therapeutics has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

Summary

Pliant Therapeutics and Bolt Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Actinium Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Bolt Biotherapeutics has lower revenue, but higher earnings than Actinium Pharmaceuticals. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Actinium Pharmaceuticals$35.09M0.96-$48.82M$0.333.24
Bolt Biotherapeutics$7.70M1.72-$33.38M-$14.97N/A

Actinium Pharmaceuticals presently has a consensus price target of $4.50, indicating a potential upside of 320.56%. Bolt Biotherapeutics has a consensus price target of $14.50, indicating a potential upside of 186.56%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Bolt Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Actinium Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Bolt Biotherapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

In the previous week, Actinium Pharmaceuticals had 3 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 9 mentions for Actinium Pharmaceuticals and 6 mentions for Bolt Biotherapeutics. Bolt Biotherapeutics' average media sentiment score of 1.03 beat Actinium Pharmaceuticals' score of 0.42 indicating that Bolt Biotherapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Actinium Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Bolt Biotherapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Actinium Pharmaceuticals has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

Actinium Pharmaceuticals has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Actinium Pharmaceuticals' return on equity of -100.85% beat Bolt Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Actinium PharmaceuticalsN/A -100.85% -47.89%
Bolt Biotherapeutics -611.47%-154.11%-57.59%

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 0.9% of Actinium Pharmaceuticals shares are owned by insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Actinium Pharmaceuticals beats Bolt Biotherapeutics on 8 of the 15 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Bolt Biotherapeutics has higher revenue and earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Werewolf Therapeutics$1.88M25.48-$60.82M-$0.60N/A
Bolt Biotherapeutics$7.70M1.72-$33.38M-$14.97N/A

In the previous week, Bolt Biotherapeutics had 4 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 6 mentions for Bolt Biotherapeutics and 2 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 2.04 beat Bolt Biotherapeutics' score of 1.03 indicating that Werewolf Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Werewolf Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Bolt Biotherapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by company insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Werewolf Therapeutics has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

Werewolf Therapeutics has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Bolt Biotherapeutics' return on equity of -154.11% beat Werewolf Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Werewolf TherapeuticsN/A -187.29% -57.88%
Bolt Biotherapeutics -611.47%-154.11%-57.59%

Werewolf Therapeutics currently has a consensus target price of $2.50, indicating a potential upside of 153.63%. Bolt Biotherapeutics has a consensus target price of $14.50, indicating a potential upside of 186.56%. Given Bolt Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Werewolf Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Bolt Biotherapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Summary

Bolt Biotherapeutics beats Werewolf Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Gain Therapeutics?

Bolt Biotherapeutics (NASDAQ:BOLT) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

In the previous week, Gain Therapeutics had 4 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 10 mentions for Gain Therapeutics and 6 mentions for Bolt Biotherapeutics. Bolt Biotherapeutics' average media sentiment score of 1.03 beat Gain Therapeutics' score of 1.01 indicating that Bolt Biotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bolt Biotherapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Gain Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Gain Therapeutics has lower revenue, but higher earnings than Bolt Biotherapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bolt Biotherapeutics$7.70M1.72-$33.38M-$14.97N/A
Gain Therapeutics$50K935.13-$20.16M-$0.42N/A

Gain Therapeutics has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Gain Therapeutics' return on equity of -133.17% beat Bolt Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bolt Biotherapeutics-611.47% -154.11% -57.59%
Gain Therapeutics N/A -133.17%-102.45%

Bolt Biotherapeutics has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 9.4% of Bolt Biotherapeutics shares are owned by company insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Bolt Biotherapeutics presently has a consensus price target of $14.50, suggesting a potential upside of 186.56%. Gain Therapeutics has a consensus price target of $7.67, suggesting a potential upside of 630.16%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Gain Therapeutics is more favorable than Bolt Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bolt Biotherapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Gain Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Summary

Gain Therapeutics beats Bolt Biotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Connect Biopharma?

Bolt Biotherapeutics (NASDAQ:BOLT) and Connect Biopharma (NASDAQ:CNTB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Bolt Biotherapeutics currently has a consensus price target of $14.50, indicating a potential upside of 186.56%. Connect Biopharma has a consensus price target of $5.88, indicating a potential upside of 835.21%. Given Connect Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Connect Biopharma is more favorable than Bolt Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bolt Biotherapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Connect Biopharma
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.78

Connect Biopharma has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Bolt Biotherapeutics' return on equity of -154.11% beat Connect Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Bolt Biotherapeutics-611.47% -154.11% -57.59%
Connect Biopharma N/A -220.02%-145.03%

Bolt Biotherapeutics has higher revenue and earnings than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bolt Biotherapeutics$7.70M1.72-$33.38M-$14.97N/A
Connect Biopharma$60K659.30-$55.48M-$1.14N/A

86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 9.4% of Bolt Biotherapeutics shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Connect Biopharma had 6 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 12 mentions for Connect Biopharma and 6 mentions for Bolt Biotherapeutics. Bolt Biotherapeutics' average media sentiment score of 1.03 beat Connect Biopharma's score of 0.52 indicating that Bolt Biotherapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bolt Biotherapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Connect Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Bolt Biotherapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Connect Biopharma has a beta of 0.06, meaning that its share price is 94% less volatile than the broader market.

Summary

Bolt Biotherapeutics and Connect Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

Get Bolt Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BOLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BOLT vs. The Competition

MetricBolt BiotherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$13.30M$3.98B$7.59B$11.70B
Dividend YieldN/A3.64%2.48%4.65%
P/E Ratio-0.3425.7931.9926.76
Price / Sales1.7215.788.405.53
Price / CashN/A22.6520.7221.66
Price / Book1.544.294.423.65
Net Income-$33.38M-$23.99M$3.51B$394.00M
7 Day Performance-16.78%-6.11%-5.44%-5.74%
1 Month Performance17.40%-11.62%-8.62%-9.54%
1 Year Performance5.42%-4.96%-1.31%-6.71%

Bolt Biotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BOLT
Bolt Biotherapeutics
3.2669 of 5 stars
$5.06
-0.8%
$14.50
+186.6%
+8.1%$13.30M$7.70MN/A23
PLRX
Pliant Therapeutics
1.3847 of 5 stars
$0.79
-1.7%
$3.00
+281.8%
-58.7%$49.51M$1.58MN/A49
ATNM
Actinium Pharmaceuticals
2.6282 of 5 stars
$1.57
+1.9%
$5.00
+218.5%
-21.3%$49.36M$35.09MN/A25
HOWL
Werewolf Therapeutics
2.9627 of 5 stars
$0.97
-4.0%
$4.00
+312.4%
+6.6%$49.08M$1.88MN/A14
GANX
Gain Therapeutics
2.2881 of 5 stars
$1.08
-0.9%
$7.67
+609.9%
-61.8%$47.57M$50KN/A21

Related Companies and Tools


This page (NASDAQ:BOLT) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners